{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T04:01:47Z","timestamp":1749355307538,"version":"3.41.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,7]]},"DOI":"10.7759\/cureus.85494","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T08:12:34Z","timestamp":1749283954000},"source":"Crossref","is-referenced-by-count":0,"title":["A Refractory, Gas-Predominant Subgroup of Irritable Bowel Syndrome Markedly Improved With Relatively Long-Term Paroxetine Treatment: A Preliminary Study"],"prefix":"10.7759","author":[{"given":"Kazunori","family":"Mine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munechika","family":"Enjoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Mearin F","year":"2016","unstructured":"Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. Gastroenterology. 2016, 150:1393-407.E5. 10.1053\/j.gastro.2016.02.031","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.07.008","article-title":"Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome","volume":"7","author":"Ringel Y","year":"2009","unstructured":"Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009, 7:68-72. 10.1016\/j.cgh.2008.07.008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.04.039","article-title":"AGA clinical practice update on evaluation and management of belching, abdominal bloating, and distention: expert review","volume":"165","author":"Moshiree B","year":"2023","unstructured":"Moshiree B, Drossman D, Shaukat A. AGA clinical practice update on evaluation and management of belching, abdominal bloating, and distention: expert review. Gastroenterology. 2023, 165:791-800.e3. 10.1053\/j.gastro.2023.04.039","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01009.x","article-title":"Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome","volume":"94","author":"Lembo T","year":"1999","unstructured":"Lembo T, Naliboff B, Munakata J, et al.. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol. 1999, 94:1320-6. 10.1111\/j.1572-0241.1999.01009.x","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.299.6708.1138","article-title":"Ranking of symptoms by patients with the irritable bowel syndrome","volume":"299","author":"Maxton DG","year":"1989","unstructured":"Maxton DG, Morris JA, Whorwell PJ. Ranking of symptoms by patients with the irritable bowel syndrome. BMJ. 1989, 299:1138. 10.1136\/bmj.299.6708.1138","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i22.6759","article-title":"Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine","volume":"20","author":"Saha L","year":"2014","unstructured":"Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014, 20:6759-73. 10.3748\/wjg.v20.i22.6759","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.07.013","article-title":"Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial","volume":"160","author":"Holvoet T","year":"2021","unstructured":"Holvoet T, Joossens M, V\u00e1zquez-Castellanos JF, et al.. Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial. Gastroenterology. 2021, 160:145-157.e8. 10.1053\/j.gastro.2020.07.013","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001767","article-title":"Clinical characteristics of patients presenting with bloating as a predominant symptom","volume":"57","author":"Said H","year":"2023","unstructured":"Said H, Nee J, Iturrino J, Rangan V, Singh P, Lembo A, Ballou S. Clinical characteristics of patients presenting with bloating as a predominant symptom. J Clin Gastroenterol. 2023, 57:830-4. 10.1097\/MCG.0000000000001767","journal-title":"J Clin Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14202","article-title":"The Intestinal Gas Questionnaire (IGQ): psychometric validation of a new instrument for measuring gas-related symptoms and their impact on daily life among general population and irritable bowel syndrome","volume":"34","author":"Duracinsky M","year":"2022","unstructured":"Duracinsky M, Archbold S, Lobo B, et al.. The Intestinal Gas Questionnaire (IGQ): psychometric validation of a new instrument for measuring gas-related symptoms and their impact on daily life among general population and irritable bowel syndrome. Neurogastroenterol Motil. 2022, 34:e14202. 10.1111\/nmo.14202","journal-title":"Neurogastroenterol Motil"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.129","article-title":"Bloating and abdominal distension: old misconceptions and current knowledge","volume":"112","author":"Malagelada JR","year":"2017","unstructured":"Malagelada JR, Accarino A, Azpiroz F. Bloating and abdominal distension: old misconceptions and current knowledge. Am J Gastroenterol. 2017, 112:1221-31. 10.1038\/ajg.2017.129","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis CY","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997, 11:395-402. 10.1046\/j.1365-2036.1997.142318000.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2486\/indhealth.36.8","article-title":"The Japanese adaptation of the STAI Form Y in Japanese working adults-the presence or absence of anxiety","volume":"36","author":"Iwata N","year":"1998","unstructured":"Iwata N, Mishima N, Shimizu T, Mizoue T, Fukuhara M, Hidano T, Spielberger CD. The Japanese adaptation of the STAI Form Y in Japanese working adults-the presence or absence of anxiety. Ind Health. 1998, 36:8-13. 10.2486\/indhealth.36.8","journal-title":"Ind Health"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.04.028","article-title":"Severity classification on the Hamilton depression rating scale","volume":"150","author":"Zimmerman M","year":"2013","unstructured":"Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton depression rating scale. J Affect Disord. 2013, 150:384-8. 10.1016\/j.jad.2013.04.028","journal-title":"J Affect Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(91)72119-1","article-title":"Fluoxetine for obsessive fear of loss of control of malodorous flatulence","volume":"32","author":"Fishbain DA","year":"1991","unstructured":"Fishbain DA, Goldberg M. Fluoxetine for obsessive fear of loss of control of malodorous flatulence. Psychosomatics. 1991, 32:105-7. 10.1016\/S0033-3182(91)72119-1","journal-title":"Psychosomatics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2019.01545","article-title":"Socialization practices regarding shame in Japanese caregiver-child interactions","volume":"10","author":"Takada A","year":"2019","unstructured":"Takada A. Socialization practices regarding shame in Japanese caregiver-child interactions. Front Psychol. 2019, 10:1545. 10.3389\/fpsyg.2019.01545","journal-title":"Front Psychol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/09540261.2022.2148829","article-title":"Self-compassion, mental health shame and work motivation in German and Japanese employees","volume":"35","author":"Kotera Y","year":"2023","unstructured":"Kotera Y, Mayer CH, Vanderheiden E. Self-compassion, mental health shame and work motivation in German and Japanese employees. Int Rev Psychiatry. 2023, 35:113-24. 10.1080\/09540261.2022.2148829","journal-title":"Int Rev Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.10.004","article-title":"Sex- and gender-related differences in common functional gastroenterologic disorders","volume":"96","author":"Narayanan SP","year":"2021","unstructured":"Narayanan SP, Anderson B, Bharucha AE. Sex- and gender-related differences in common functional gastroenterologic disorders. Mayo Clin Proc. 2021, 96:1071-89. 10.1016\/j.mayocp.2020.10.004","journal-title":"Mayo Clin Proc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2007.10.012","article-title":"Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents","volume":"152","author":"Bahar RJ","year":"2008","unstructured":"Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr. 2008, 152:685-9. 10.1016\/j.jpeds.2007.10.012","journal-title":"J Pediatr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01523-4","article-title":"Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Ford AC","year":"2023","unstructured":"Ford AC, Wright-Hughes A, Alderson SL, et al.. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 402:1773-85. 10.1016\/S0140-6736(23)01523-4","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.50.1.78","article-title":"A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome","volume":"50","author":"Masand PS","year":"2009","unstructured":"Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, Patkar AA. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics. 2009, 50:78-86. 10.1176\/appi.psy.50.1.78","journal-title":"Psychosomatics"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"114","author":"Ford AC","year":"2019","unstructured":"Ford AC, Lacy BE, Harris LA, Quigley EM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019, 114:21-39. 10.1038\/s41395-018-0222-5","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.077503","article-title":"A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome","volume":"55","author":"Tack J","year":"2006","unstructured":"Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006, 55:1095-103. 10.1136\/gut.2005.077503","journal-title":"Gut"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014528151","article-title":"Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome","volume":"48","author":"Bundeff AW","year":"2014","unstructured":"Bundeff AW, Woodis CB. Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome. Ann Pharmacother. 2014, 48:777-84. 10.1177\/1060028014528151","journal-title":"Ann Pharmacother"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.04127.x","article-title":"Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial","volume":"99","author":"Tabas G","year":"2004","unstructured":"Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol. 2004, 99:914-20. 10.1111\/j.1572-0241.2004.04127.x","journal-title":"Am J Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.04.032","article-title":"Management options for irritable bowel syndrome","volume":"93","author":"Camilleri M","year":"2018","unstructured":"Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc. 2018, 93:1858-72. 10.1016\/j.mayocp.2018.04.032","journal-title":"Mayo Clin Proc"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4161\/gmic.29417","article-title":"The microbiota-gut-brain axis in functional gastrointestinal disorders","volume":"5","author":"De Palma G","year":"2014","unstructured":"De Palma G, Collins SM, Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes. 2014, 5:419-29. 10.4161\/gmic.29417","journal-title":"Gut Microbes"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145707007985","article-title":"Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea","volume":"11","author":"Tanaka M","year":"2008","unstructured":"Tanaka M, Kobayashi D, Murakami Y, et al.. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol. 2008, 11:261-7. 10.1017\/S1461145707007985","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2767","article-title":"Adverse effects of antidepressant medications and their management in children and adolescents","volume":"43","author":"Strawn JR","year":"2023","unstructured":"Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy. 2023, 43:675-90. 10.1002\/phar.2767","journal-title":"Pharmacotherapy"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181c8ae80","article-title":"Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome","volume":"30","author":"Murata Y","year":"2010","unstructured":"Murata Y, Kobayashi D, Imuta N, et al.. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010, 30:11-7. 10.1097\/JCP.0b013e3181c8ae80","journal-title":"J Clin Psychopharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/353969-a-refractory-gas-predominant-subgroup-of-irritable-bowel-syndrome-markedly-improved-with-relatively-long-term-paroxetine-treatment-a-preliminary-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T08:12:34Z","timestamp":1749283954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/353969-a-refractory-gas-predominant-subgroup-of-irritable-bowel-syndrome-markedly-improved-with-relatively-long-term-paroxetine-treatment-a-preliminary-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.85494","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,7]]}}}